29May 2022
Ototoxicity of Long‐Term α‐Difluoromethylornithine for Skin Cancer Prevention

Ototoxicity of Long‐Term α‐Difluoromethylornithine for Skin Cancer Prevention

This randomized controlled trial revealed the presence of increased hearing thresholds associated with long‐term DFMO use. As a whole, DFMO may help prevent and treat certain types of cancers; however, it can result in some degree of hearing loss even when administered at low doses. This study further highlights the importance of closely monitoring hearing thresholds in subjects taking DFMO.

  • #ent

Like

Save

Share